hotspot -WSS

hotspot

author：Wikipedia 2025-09-28 00:49:21 - browse：52482

Illustration of a red heart. -- health coverage from STAT — Adobe

Novo Nordisk’s obesity drug Wegovy cut the risk of major heart complications by 20% in a closely watched trial, results that could streamline insurance coverage and spur even greater demand for the highly popular therapy.

The milestone Select trial of about 17,500 patients is the first to show that an obesity medication leads to long-term cardiovascular benefits. The company reported only the topline figure in a press release Tuesday, and did not break out the reductions it said were seen in heart attacks, strokes, and cardiovascular deaths — the combined components of the study’s primary outcome. It said all three contributed to the decrease in cardiovascular events in the group that received Wegovy compared with participants given a placebo.

The 20% reduction was greater than many observers were expecting. In a research note Tuesday, Jefferies analysts called the results a “best case” outcome. “If they play baseball in Denmark,” Barclays analyst Emily Field wrote in a note, “Wegovy just hit a home run.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Wegovy, Zepbound and weight loss drugs that preserve muscle

focus

leisure time

WSS

In key trial, Verve's treatment lowers cholesterol levels in patients

World's first CRISPR

Hospitals look to new technology to keep health care workers safe

Gain of function research would be limited under House proposal

Poor hospice wound care hurts patients and families

Weight loss drug costs may need more research, senator suggests

hotspot

hotspot

entertainment

Jerome Adams on the need for new antivirals for Covid

New study raises questions about niacin and heart health

Dobbs anniversary: the lost opportunity of abortion as health care

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Apple is now the first public company to be valued at $3 trillion

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Malaria cases in Florida and Texas: Here’s what you need to know

Abridge raises $150m as clinical notes automation market heats up

23andMe had bad news about my health. I wish a person had delivered it

In key trial, Verve's treatment lowers cholesterol levels in patients

Wikipedia

U.K. considers world's first use of meningitis vaccine to address gonorrhea

In key trial, Verve's treatment lowers cholesterol levels in patients

Congress may force more Covid

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Why medical students are struggling with mental health

Astellas still sees hope in its gene therapy after four deaths

hotspot

focus

leisure time

focus